Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
United Kingdom
In shortOxford Biomedica PLC is loss-making, burns cash and holds more cash than debt, with revenue growing (+31.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -13.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -17.9% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -40.6% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -16.2% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.20× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.45× | 86/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -1.54× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -2.5% | 10/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 4 | 17/100 |
| Revenue growth volatility | 35.8% | 0/100 |
| Operating margin volatility | 87.9% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 6.4% | 52/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
GBP millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 143 | 140 | 90 | 129 | 169 |
| Cost of revenue | 60 | 71 | 50 | 76 | 103 |
| Gross profit | 83 | 69 | 40 | 53 | 66 |
| Research & development | 40 | 61 | 59 | 4.5 | 5.1 |
| Operating income | 21 | (30) | (184) | (39) | (22) |
| Interest expense | 0.9 | 17 | 9.3 | 11 | 15 |
| Pre-tax income | 20 | (46) | (189) | (47) | (32) |
| Income tax | 0.9 | (0.8) | (4.4) | 1.3 | (1.3) |
| Net income | 19 | (39) | (157) | (43) | (30) |
| Diluted EPS | £0.22 | −£0.41 | −£1.63 | −£0.42 | −£0.27 |
Not computed: a required balance-sheet item is missing.
Not computed: it needs two consecutive complete years.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Dec 31, 2025